FTC & Supreme Greens
This article was originally published in The Tan Sheet
Executive Summary
Direct Marketing Concepts, ITV Direct and Donald Barrett are barred from claiming that dietary supplement Supreme Greens with MSM treats, cures or prevents cancer, diabetes, arthritis and heart disease under a preliminary injunction obtained by the Federal Trade Commission announced July 2. The defendants also must prominently display disclaimers that infomercials aired to promote the product are paid advertisements, and may not sell or distribute products or services by means of a continuity program without informed consent from the consumer, according to the ruling. FTC filed charges in June 2004 alleging the defendants had deceptively marketed Supreme Greens through an infomercial, failed to disclose the program was a paid promotion and charged credit cards for automatic product shipments without consent...
You may also be interested in...
Supreme Greens settlement
Supreme Greens developer Alejandro Guerrero and his company Health Solutions will pay $65,000 or transfer to FTC the title to Guerrero's 2004 Cadillac Escalade for allegedly claiming that Supreme Greens could prevent, treat or cure cancer, heart disease, arthritis and diabetes, the commission announces Oct. 6. The herbal supplement also was promoted for substantial weight loss. Healthy Solutions and two other individuals will also pay a combined total of $15,000. The settlement has two avalanche clauses for a $4.17 mil. total. FTC filed the complaint in June 2004, litigation is still pending against ITV Direct, Direct Marketing Concepts and other others (1"The Tan Sheet" July 5, 2004, In Brief) ...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.